Senescence-associated adhesion molecule 1 (SAAM-1)

Senescence-associated adhesion molecule 1 (SAAM-1) is a novel cell-surface transmembrane protein identified as a specific marker for senescent cells, particularly in vascular endothelial tissues. Discovered through single-cell RNA sequencing by researchers at Juntendo University, SAAM-1 expression is significantly upregulated during cellular senescence and correlates with the progression of age-related cardiovascular pathologies such as atherosclerosis and heart failure. As a "seno-antigen," it serves as a therapeutic target for senolytic vaccines designed to trigger an adaptive immune response, leading to the selective elimination of senescent cells via antibody-dependent cellular cytotoxicity (ADCC). Preclinical studies have demonstrated that targeting SAAM-1 can reduce the senescence burden in the aorta and heart, thereby improving cardiac function, reducing fibrosis, and suppressing atherosclerotic plaque formation. This approach represents a promising strategy for mitigating chronic inflammation and tissue remodeling associated with pathological aging.

Other names

SAAM1Seno-antigen SAAM-1Senescence-associated transmembrane protein